EUCTR2009-016930-29-IT进行中(未招募)不适用
Ranolazine to treat early cardiotoxicity induced by antitumor drugs - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18-70 years 2. Eastern Cooperative Oncology Group performance status of 0 to 1 3. total serum bilirubin < 2.0 mg/dL 4. serum creatinine level < 2.0 mg/dL 5. normal ECG 6. LVEF ≥ 50% at echocardiography 7. normal E/A and DcT at echocardiography 8. no significant perfusion defect at SPECT 9. able to release written informed consent 10. women of childbearing potential must have a negative serum pregnancy test; they agree on avoiding pregnancy by adequate contraceptive precautions (e.g., double barrier methods), or abstinence, during both chemotherapy and subsequent ranolazine therapy (if applicable) 11. male patients are informed of the mutagenic and embryotoxic effects of chemotherapy; in agreement with their partner, they accept not to concur in a pregnancy by adopting adequate contraceptive precautions, or abstinence, during chemotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. pregnancy or nursing 2. women with HER-2+ breast cancer requiring post-chemotherapy trastuzumab 3. prior chemotherapy or medastinal irradiation 4. patients with mediastinal lymphoma liable to irradiation after completing chemotherapy 5. long QTc, LVEF < 50% or altered E/A, or significant perfusion defects, at screening ECG, echocardiography, and SPECT 6. hypertension 7. any clinically documented heart disease 8. any other medical conditions that required treatment over the past 3 months with ACEI, ABR, Ca2+ antagonists, β blockers, nitrates, diuretics 9. diabetes mellitus 10. dislipidemia 11. BMI > 30 12. prior steroid pulse therapy for unrelated diseases 13. severe renal impairment 14. moderate or severe hepatic impairment 15. cerebral vascular accidents within the past 3 months 16. severe psychopathy 17. chronic obstructive lung disease
研究者
相似试验
进行中(未招募)
不适用
Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial IschemiaCAD with acute ischemia and myocardial dysfunctionMedDRA version: 14.1Level: PTClassification code 10028600Term: Myocardial ischaemiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2013-000030-35-DEniversity Medical Center Hamburg-Eppendorf
尚未招募
3 期
RanolazIne for heart failure with preServed Ejection fraction: [RISE - HFpEF study]CTRI/2022/02/040351Indian Council of Medical Research ICMR
进行中(未招募)
1 期
A pilot study assessing the effects of Ranolazine on small heart vessels dysfunction in patients with hypertrophic cardiomyopathyHypertrophic cardiomyopathyEUCTR2015-004402-42-ITOSPEDALE SAN RAFFAELE24
Unknown
4 期
Study to Reduce Symptoms of Premature Beats With RanolazinePremature Ventricular BeatsNCT01996618Walter Reed National Military Medical Center72
已完成
2 期
Ranolazine Mediated PVC Reduction in Ischemic Heart DiseaseVentricular Premature ComplexesMyocardial IschemiaNCT02360397Kent Hospital, Rhode Island6
